Brought to you by 
GSK invests £1.25mm in hearing loss spin-out Autifony, out-licenses candidates
04 Oct 2011
Executive Summary
For a 25.4% stake, GlaxoSmithKline PLC’s Glaxo Group Ltd. is investing £1.25mm ($2.06mm) into its hearing loss spin-out Autifony Therapeutics Ltd., which is issuing the Big Pharma 850k A ordinary shares.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK invests £1.25mm in hearing loss spin-out Autifony, out-licenses candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice